tbuckley/cabot-search huggingface dataset:
Correlation between HER2/neu status with immunohistochemical analysis and serum HER2 concentration with ADVIA Cencaur automated immunoassay in breast cancer
Authors: J. Lee, S. Ahn
Journal: Journal of Clinical Oncology (2008)

1111 Background: Serum HER2/neu is extracted from extracelluar domain of HER2/neu tyrosine kinase to serum. We evaluated the correlation between HER2/neu status with immunochemical analysis and serum HER2/neu concentration among Korean women with breast cancer. Methods: Serum HER2 levels were examined among 254 patients with primary breast cancer and 38 patients with metastatic breast cancer by Chemiluminescence immunoassay during preoperative period. All breast cancer tissues were tested by IHC for HER2/neu, and underwent FISH analysis for IHC+2. The cut-off value was 10.2 ng/ml. Results: Mean serum HER2/neu level was 10.1 ng/ml in primary breast cancer. Serum HER2/neu concentration was significantly correlated with tissue IHC analysis (grade 1:9.3±1.7, grade 2: 9.0±1.7, grade 3: 12.2±4.0ng/ml, p<0.001). Increased serum HER2/neu levels were associated with lymph node status (p=0.003) and hormone unresponsiveness (p<0.001), tumor size (p<0.013), age group (p<0.001). In metastatic breast cancer, mean serum HER2/neu level was 13.6 ng/ml. Elevated serum HER2/neu was 71.7% in metastatic breast cancer. Serum HER2/neu was correlated with metastatic tisse IHC analysis (p<0.001) rather than HER2/neu status of its’ primary breast cancer (p=0.16). Conclusions: Serum HER2/neu seem to be correlated with tissue HER2/neu expression in HER2-overexpressed primary and metastatic breast cancer. Serum HER2 is necessary to have futher study for determine cuttoff value and various clinical application of breast cancer in Korea. No significant financial relationships to disclose.
Neurodevelopmental Implications of Fetal Exposure to Selective Serotonin Reuptake Inhibitors and Untreated Maternal Depression
Authors: Lee S. Cohen, Ruta Nonacs
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Improved Survival in Peripheral T-Cell Lymphoma (PTCL) Following Complete Response to First-Line Chemotherapy: 10 Year Experience at the Royal Marsden and the Christie Hospitals 2002-2012
Authors: Mary Gleeson, Kim Linton, Clare Peckitt, Adam Gibb, Eliza A Hawkes, Morgan Back, Binnaz Yasar, Kate Foley, Rebecca Lee, Joanna Dash, Hannah Johnson, Catherine O'Hara, Andrew Wotherspoon, Ayoma Attygalle, Michael Potter, Mark E Ethell, Claire Dearden, John Radford, Ian Chau, David Cunningham
Journal: Blood (2015)
Body Mass Index, Waist Circumference, Diabetes, and Risk of Liver Cancer for U.S. Adults
Authors: Peter T. Campbell, Christina C. Newton, Neal D. Freedman, Jill Koshiol, Michael C. Alavanja, Laura E. Beane Freeman, Julie E. Buring, Andrew T. Chan, Dawn Q. Chong, Mridul Datta, Mia M. Gaudet, J. Michael Gaziano, Edward L. Giovannucci, Barry I. Graubard, Albert R. Hollenbeck, Lindsey King, I.-Min Lee, Martha S. Linet, Julie R. Palmer, Jessica L. Petrick, Jenny N. Poynter, Mark P. Purdue, Kim Robien, Lynn Rosenberg, Vikrant V. Sahasrabuddhe, Catherine Schairer, Howard D. Sesso, Alice J. Sigurdson, Victoria L. Stevens, Jean Wactawski-Wende, Anne Zeleniuch-Jacquotte, Andrew G. Renehan, Katherine A. McGlynn
Journal: Cancer Research (2016)

Abstract Incidence rates for liver cancer have increased 3-fold since the mid-1970s in the United States in parallel with increasing trends for obesity and type II diabetes mellitus. We conducted an analysis of baseline body mass index (BMI), waist circumference (WC), and type II diabetes mellitus with risk of liver cancer. The Liver Cancer Pooling Project maintains harmonized data from 1.57 million adults enrolled in 14 U.S.-based prospective studies. Cox regression estimated HRs and 95% confidence intervals (CI) adjusted for age, sex, study center, alcohol, smoking, race, and BMI (for WC and type II diabetes mellitus). Stratified analyses assessed whether the BMI–liver cancer associations differed by hepatitis sera-positivity in nested analyses for a subset of cases (n = 220) and controls (n = 547). After enrollment, 2,162 incident liver cancer diagnoses were identified. BMI, per 5 kg/m2, was associated with higher risks of liver cancer, more so for men (HR = 1.38; 95% CI, 1.30–1.46) than women (HR = 1.25; 95% CI, 1.17–1.35; Pinteraction = 0.02). WC, per 5 cm, was associated with higher risks of liver cancer, approximately equally by sex (overall, HR = 1.08; 95% CI, 1.04–1.13). Type II diabetes mellitus was associated with higher risk of liver cancer (HR = 2.61; 95% CI, 2.34–2.91). In stratified analyses, there was a null association between BMI and liver cancer risk for participants who were sera-positive for hepatitis. This study suggests that high BMI, high WC, and type II diabetes mellitus are associated with higher risks of liver cancer and that the association may differ by status of viral hepatitis infection. Cancer Res; 76(20); 6076–83. ©2016 AACR.
TCT-101 Experience with cerebral protection during transcatheter aortic valve replacement: the ALSTER registry
Authors: Tobias Schmidt, Ulrich Schäfer, Ozan Akdag, Oscar D. Sanchez, Elena Ladich, Thielsen Thomas, Michael Schlüter, Dimitry Schewel, Jury Schewel, Felix Kreidel, Hannes Alessandrini, Karl-Heinz Kuck, Christian Frerker
Journal: Journal of the American College of Cardiology (2015)
Natural Scaffold, from Bovine Bone Marrow, Reproduces Native Microenvironment and Supports CD34+ and Stromal Cells
Authors: Renata Giardini Rosa, Juares E. Romero Bianco, Gabriela Pereira dos Santos, Stephen D. Waldman, Joanna Weber, Paulo P. Joazeiro, Sara Teresinha Olalla Saad
Journal: Blood (2015)
Factors influencing the infant gut microbiome at age 3-6 months: Findings from the ethnically diverse Vitamin D Antenatal Asthma Reduction Trial (VDAART)
Authors: Joanne E. Sordillo, Yanjiao Zhou, Michael J. McGeachie, John Ziniti, Nancy Lange, Nancy Laranjo, Jessica R. Savage, Vincent Carey, George O'Connor, Megan Sandel, Robert Strunk, Leonard Bacharier, Robert Zeiger, Scott T. Weiss, George Weinstock, Diane R. Gold, Augusto A. Litonjua
Journal: Journal of Allergy and Clinical Immunology (2016)
Aberrant DNA Methylation in Childhood Acute Lymphoblastic Leukemia as a Potential Biomarker Reflecting Disease Status.
Authors: Seung Yeon Kwon, Sung Chul Won, Hyo Sun Kim, Hei-Cheul Jeung, Sun Young Rha, Kyu Hyun Park, Jaewoo Song, Chuhl Joo Lyu
Journal: Blood (2009)
Synergistic thermoradiotherapy based on PEGylated Cu 3 BiS 3 ternary semiconductor nanorods with strong absorption in the second near-infrared window
Authors: Ang Li, Xiang Li, Xujiang Yu, Wei Li, Ruyi Zhao, Xiao An, Daxiang Cui, Xiaoyuan Chen, Wanwan Li
Journal: Biomaterials (2016)
99mTc-Sestamibi Avid Soft Tissue Lesions in Rosai-Dorfman Disease
Authors: Philip Kin-Wai Wong, Daniel J. Lee, Saul Harari, Bruce J. Barron
Journal: Clinical Nuclear Medicine (2016)

Langerhan's histiocytosis is a not uncommon disease, but a related disorder, Rosai-Dorfman (RDD) with extensive or exclusive extranodal distribution, is relatively rare. Ga and PET/CT imaging have typically been used for diagnosis and tracking response to treatment. The authors present a very unusual case wherein lesions of RDD actively accumulated Tc-sestamibi, which was injected as part of a scan to localize a parathyroid adenoma.
GW27-e0776 Impacts of Different Serum Glucose Level on The Anti-Platelet Effect of Clopidogrel and Ticagrelor in Patients with Acute Myocardial Infarction Complicated by Type 2 Diabetes
Authors: Zhang Haozhou, Liu Zhuomin, Wang Jingping
Journal: Journal of the American College of Cardiology (2016)
TCT-291 Comparison of Simplified and Comprehensive Methods for Assessing the Index of Microvascular Resistance in Heart Transplant Recipients
Authors: Ole Geir Solberg, Lars Aaberge, Marit Aas, Knut Endresen, Lars Gullestad, Asgrimur Ragnarsson, Jūratė Šaltytė Benth, Knut Stavem
Journal: Journal of the American College of Cardiology (2015)
TCT-257 Frequency and clinical impact of prasugrel cessation after primary PCI in STEMI patients: a prospective cohort study
Authors: Lorenz Raber, Thomas Zanchin, Dik Heg, Roland Klingenberg, Baris Gencer, Andreas Baumbach, Marco Roffi, Olivier Muller, Bernhard Meier, Thomas F. Lüscher, Peter Jüni, Christian M. Matter, Stephan Windecker
Journal: Journal of the American College of Cardiology (2015)
Successful Repeated Peptide Receptor Radionuclide Therapies in Renal Neuroendocrine Tumor With Osseous Metastasis
Authors: Anna Yordanova, Karin Mayer, Markus Essler, Hojjat Ahmadzadehfar
Journal: Clinical Nuclear Medicine (2016)

Renal neuroendocrine tumor (NET) is an extremely rarely occurring disease. The sporadic reports in the literature are mostly case reports, or less commonly small studies. In cases of metastatic disease from renal NET, there are no established therapies. We are reporting our experience with a patient with extensive osseous infiltration of a renal NET, who was successfully treated with peptide receptor radionuclide therapy (PRRT) using Lu-DOTATATE. In a period of 10 years, the patient underwent in total 12 cycles of PRRT with a cumulative dose of 81 GBq. All therapies were unproblematic and well tolerated.
A Population-Based Study of Cardiovascular Mortality Following Early-Stage Breast Cancer
Authors: Husam Abdel-Qadir, Peter C. Austin, Douglas S. Lee, Eitan Amir, Jack V. Tu, Paaladinesh Thavendiranathan, Kinwah Fung, Geoffrey M. Anderson
Journal: JAMA Cardiology (2016)

There is increasing interest in the effect of cardiovascular disease on cancer survivors. However, there are limited contemporary population-based data on the risk of cardiovascular death after early-stage breast cancer.To describe the incidence of cardiovascular death in a contemporary population of women with early-stage breast cancer while accounting for competing risks.A population-based cohort study was conducted among 98 999 women diagnosed with early-stage breast cancer between April 1, 1998, and March 31, 2012. Patients were followed up until death or were censored on December 31, 2013. Baseline characteristics were determined from administrative databases and the Ontario Cancer registry. Vital statistics data were used to determine the cause of death. Cumulative incidence functions were used to estimate the incidence of cause-specific mortality. We studied the association between baseline characteristics and rates of cardiovascular death using cause-specific hazard functions. The analyses accounted for competing risks of noncardiovascular death. Statistical analysis was performed from July 16, 2015, to August 4, 2016.Early-stage breast cancer, age, cardiovascular disease, hypertension, and diabetes.Cause of death, which was classified as breast cancer, cardiovascular disease, other cancers, or other noncancer causes.Of the 98 999 women (median age, 60 years [interquartile range, 50-71 years]) in the study, 21 123 (21.3%) died during follow-up. The median time to death was 4.2 years (IQR, 2.2-7.1 years). Breast cancer was the most common cause of death (10 550 deaths [49.9%]); 3444 deaths [16.3%] were from cardiovascular causes. Cardiovascular death was infrequent in women younger than 66 years without prior cardiovascular disease, diabetes, or hypertension. Among women 66 years or older, the risks of breast cancer death and cardiovascular death at 10 years were 11.9% (95% CI, 11.6%-12.3%) and 7.6% (95% CI, 7.3%-7.9%), respectively. Among patients with prior cardiovascular disease, the risk of death from breast cancer and cardiovascular disease were equivalent for the first 5 years, after which death from cardiovascular causes was more frequent (10-year cumulative incidence, 14.6% [95% CI, 13.7%-15.4%] for breast cancer vs 16.9% [95% CI, 16.0%-17.8%] for cardiovascular disease). For women 66 years or older who survived 5 years or more after diagnosis of breast cancer, cardiovascular disease exceeded breast cancer as the leading cause of death at 10 years after diagnosis, when the cumulative incidence of each was 5%.Cardiovascular death is an important competing risk for older women with early-stage breast cancer. This finding mandates adequate attention to cardiovascular preventive therapy after diagnosis of breast cancer.
STUDIES ON SUSCEPTIBILITY TO INFECTION FOLLOWING IONIZING RADIATION
Authors: C. Phillip Miller, Carolyn W. Hammond, Sonia K. Anderle
Journal: The Journal of Experimental Medicine (1960)

Ten week old female CF-1 mice were subjected to a single total body exposure of x-radiation in one of the following doses: 300, 400, and 500 r. At intervals thereafter, susceptibility to bacterial infection was determined by intraperitoneal challenge with graded inocula of Pseudomonas aeruginosa. Mice exposed to 400 or 500 r were also challenged by intravenous inoculation. The LD(50) of the test microorganism in each challenge was estimated from the mortality data. Exposure to 300 r caused little increase in susceptibility to this experimental infection. 400 r caused a moderate increase on the 3rd day post-irradiation with return to normal on the 17th. Leucocyte counts (geometric means) following this dose of radiation did not fall below 1200. 500 r caused a marked increase in susceptibility which lasted from the 3rd to 11th day, during which period the leucocyte counts were below 800. On the 20th day, susceptibility to infection was normal, although the geometric mean of leucocyte counts was only 2200. Comparison of mortalities resulting from equivalent inocula introduced by the two routes (intravenous and intraperitoneal) showed no difference in unirradiated mice. However, among mice irradiated with 400 or 500 r, higher mortalities resulted from intravenous inoculation. The difference was found to be due to the establishment of a small focus of infection at the site of intravenous injection as a result of leakage of a minute fraction of inoculum into the perivenous tissues of the tail. Bacterial multiplication occurred in such foci in irradiated (leucopenic) mice, but not in unirradiated mice, nor at the site of intraperitoneal inoculation even in irradiated mice.
TCT-330 Insulin resistance is useful index for cardiovascular risk stratification in diabetic patients
Authors: Mineok Chang, Pum Joon Kim, Yoon Seok Koh, Jong Min Lee, Jin-Jin Kim, Byung-Hee Hwang, Ik Jun Choi, Sungmin Lim, Eun Ho Choo, Ki-Bae Seung
Journal: Journal of the American College of Cardiology (2015)
Sp1 expression is associated with increased VEGF, advanced stage, and poor survival in patients with resected gastric cancer (GC)
Authors: J. E. Mares, J. Yao, L. Wang, D. Wei, W. Gong, M. Hassan, T.-T. Wu, P. Mansfield, J. A. Ajani, K. Xie
Journal: Journal of Clinical Oncology (2004)

4039 Background: Survival of patients with resected GC remains suboptimal. Sp1 is a transcription factor that regulates the expression of multiple genes involved in angiogenesis and metastasis. Methods: GC tissue from 86 patients who had gastrectomy at the University of Texas M.D. Anderson Cancer Center was evaluated for expression of Sp1 and VEGF by Western blot and immunohistochemistry. None had pre-operative chemotherapy and/or radiation. Chi-square and logistic regression analyses were used to test the association between study parameters. Kaplan Meier and Cox proportional hazard modeling analyses were used to assess the affect of study parameters on overall survival. Results: Strong, weak, and negative Sp1 expression was observed in 24%, 56%, and 20% of cases respectively. Similarly, strong, weak, and negative VEGF expression was observed in 27%, 57%, and 16% of cases. VEGF highly correlated with Sp1 (P<.0001). Early (stage IA) GC was associated with negative and weak Sp1 expression while more advanced GC (IB-IV) was associated with strong expression (P=.035). Strong Sp1 expression was also associated with increased number (N2/N3) of nodal metastases (P=.034). The median survival for patients with negative, weak, and strong Sp1 expression was 43, 36, and 8 months respectively (P=.0003). Sp1 and VEGF expression, stage, completeness of resection, age, and histology were entered in a multivariate Cox proportional hazards model. Strong Sp1 expression (P=.021) and advanced stage (P<.001) were the only independent predictors of poor survival. VEGF did not significantly affect survival. Conclusions: This study suggests that Sp1 controls pathways that mediate the aggressive behavior of GC. Sp1 may be a useful molecular marker for selecting patients with a poor prognosis to receive more aggressive preoperative or adjuvant therapy in clinical trials. No significant financial relationships to disclose.
GW27-e0323 Echocardiography in the Demonstration of Fetal Congenital Cardiovascular Disease
Authors: Wang Yu, Hai-Yan Cao, Ming-Xing Xie, Lin He, Wei Han, Liu Hong, Yuan Peng, Yun-Fei Hu, Ben-Cai Song, Jing Wang, Bin Wang, Cheng Deng, Yu-Xin Ning
Journal: Journal of the American College of Cardiology (2016)
5-Azacytidine Specifically Depletes Regulatory T Cells (Tregs) in Myelodysplastic Syndrome (MDS) Patients
Authors: Benedetta Costantini, Shahram Y Kordasti, Austin G Kulasekararaj, Jie Jiang, Thomas Seidl, Pilar Perez Abellan, Janet Hayden, Farzin Farzaneh, Ghulam J. Mufti
Journal: Blood (2011)
Open-label, phase I/randomized, phase II trial of the triple angiokinase inhibitor, nintedanib, versus sorafenib in previously untreated patients with advanced hepatocellular carcinoma (HCC).
Authors: Daniel H. Palmer, Markus Peck-Radosavljevic, Yuk Ting Ma, Janet Graham, Laetitia Fartoux, Richard Hubner, Arsene Bienvenu Loembe, Matus Studeny, Julia Hocke, Tim Meyer
Journal: Journal of Clinical Oncology (2013)

TPS4160 Background: While sorafenib is established as the standard first-line treatment for patients with advanced HCC, its use can be complicated by the occurrence of drug-related adverse events (AEs). Nintedanib, a potent, oral triple angiokinase inhibitor that targets VEGF, PDGF and FGF signaling (as well as Flt3 and RET), has demonstrated clinical activity in various advanced solid tumors with a relatively low incidence of AEs typically associated with angiogenesis inhibitors (e.g. skin toxicity, hypertension, hemorrhage, and hematologic toxicity) and is currently in phase III for non-small cell lung cancer and ovarian cancer. In the Phase I, dose-finding stage of this ongoing, multicenter, open-label Phase I/II trial (NCT01004003), 200mg twice daily (bid) was established as the maximum tolerated dose of nintedanib in previously untreated patients with advanced HCC (Palmer D, et al. Ann Oncol 2012;23(Suppl 9):ix245[Abs 740P]). Nintedanib had an acceptable liver AE profile; the most common AEs were mild/moderate gastrointestinal toxicities. Methods: The randomized Phase II stage of the trial aims to assess the efficacy, safety, and pharmacokinetics of nintedanib in comparison with sorafenib. Eligible patients have pathologically confirmed, measurable HCC that is not amenable to local therapy, ECOG Performance Status of ≤2, Child-Pugh score of 5–6 (Class A), AST/ALT levels ≤2× upper limit of normal, and no prior systemic therapy. Patients are being stratified by macrovascular invasion and/or extrahepatic spread and then randomized 2:1 to receive nintedanib 200mg bid or sorafenib 400mg bid in continuous 28-day cycles until progression or unacceptable toxicity. Overall, 93 patients were randomized between Sept 2011 and Nov 2012. The primary endpoint is time to progression (TTP) by independent review, according to RECIST 1.0. TTP will be estimated in the treated set by Kaplan–Meier methodology with treatment effects compared using a Cox proportional hazards model. Secondary endpoints include overall survival, tumor response, progression-free survival, safety and pharmacokinetics. Results are due late 2013. Clinical trial information: NCT01004003.
TCT-13 Clinical outcomes after implantation of Absorb BVS in small vessels: results from the Italian RAI multicenter registry
Authors: Giulia Masiero, Giuseppe Tarantini, Marco Mojoli, Attilio Varricchio, Alfonso Ielasi, Bernardo Cortese, Francesco Granata, Elisabetta Moscarella, Maurizio Tespili, Roberto Adriano Latini, Paola Tellaroli, Donatella Corrado, Giuseppe Steffenino
Journal: Journal of the American College of Cardiology (2015)
Abstract A13: Anti-CD38-attenukine: A myeloma-targeting immunocytokine containing an engineered IFNα that provides &amp;gt;10,000-fold enhanced tumor-specific activity compared to native IFNα.
Authors: Sarah Pogue, Tetsuya Taura, Mingying Bi, Glen Mikesell, Yong Yun, Angela Sho, Eric Sanchez, Haiming Chen, James Berenson, Collette Behrens, Maxwell Stevens, Teresa Domagala, Maya Sokolovsky, Hussein Hallak, Moti Rosenstock, Anthony Doyle, David Wilson
Journal: Clinical Cancer Research (2015)

Abstract Multiple myeloma (MM) remains an incurable disease despite recent approvals of novel therapies. Treatments which utilize alkylating agents, corticosteroids, proteasome inhibitors and immunomodulatory drugs have provided significant survival benefits; however, tumor relapse eventually occurs with the use of these agents. The cytokine, interferon-α (IFNα), has been used clinically to treat MM for over 30 years. IFNα exerts good anti-myeloma tumor activity but durable responses are rarely achieved due to dose limiting toxicities. Tumor specificity can be modestly increased by attaching IFNα to an anti-CD38 antibody, thus targeting the cytokine to MM cells. However, by introducing an attenuating mutation to the IFNα portion of this fusion protein, the activity of the cytokine is dramatically reduced on CD38 negative cells while exhibiting a similar potency to native IFNα on CD38+ MM cells. As a result, the anti-CD38-attenuated IFNα, referred to as anti-CD38-attenukine™, has over 10,000-fold greater myeloma-specificity than native IFNα in vitro. In vivo, even though the off-target activity is decreased, anti-CD38-attenukine™ has profound anti-tumor effects in murine MM and NHL xenograft models. Treatment with this fusion protein can cure mice with large (&amp;gt;700mm3) tumors—an effect not observed with any other MM agents tested. Here we report that in a Velcade (bortezomib) refractory, IFNα-insensitive primary MM xenograft model, the combination of Velcade with anti-CD38-attenukine™ has potent anti-tumor activity, resulting in tumour elimination and curing of mice. Our findings indicate that anti-CD38-attenukine™ may be a well tolerated, potent anti-MM treatment that may be utilized alone or in combination with Velcade. Citation Format: Sarah Pogue, Tetsuya Taura, Mingying Bi, Glen Mikesell, Yong Yun, Angela Sho, Eric Sanchez, Haiming Chen, James Berenson, Collette Behrens, Maxwell Stevens, Teresa Domagala, Maya Sokolovsky, Hussein Hallak, Moti Rosenstock, Anthony Doyle, David Wilson. Anti-CD38-attenukine: A myeloma-targeting immunocytokine containing an engineered IFNα that provides &amp;gt;10,000-fold enhanced tumor-specific activity compared to native IFNα. [abstract]. In: Proceedings of the AACR Special Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; Sep 20-23, 2014; Philadelphia, PA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(17 Suppl):Abstract nr A13.